SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+13.25%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$731M
AUM Growth
+$731M
(+5.8%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
4.21%
Top 10 Holdings %
Top 10 Hldgs %
42.41%
Holding
130
New
31
Increased
26
Reduced
26
Closed
31
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$37M |
| 2 |
Novo Nordisk
NVO
|
$20.9M |
| 3 |
Bristol-Myers Squibb
BMY
|
$11.9M |
| 4 |
UroGen Pharma
URGN
|
$11.4M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$11.2M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$20.3M |
| 2 |
Viatris
VTRS
|
$19.1M |
| 3 |
Ituran Location and Control
ITRN
|
$14.6M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$11.9M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$10.2M |
Sector Composition
| 1 | Healthcare | 82.83% |
| 2 | Technology | 9.84% |
| 3 | Consumer Discretionary | 1.78% |
| 4 | Industrials | 1.62% |
| 5 | Communication Services | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $42M | 3.83% | 879,900 +249,900 | +40% | +$11.9M |
|
|
2
Johnson & Johnson
JNJ
$427B
| $37M | 3.38% | +265,000 | New | +$37M |
|
3
Amicus Therapeutics
FOLD
$2.34B
| $33.8M | 3.09% | 2,488,078 +40,084 | +2% | +$545K |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $33.4M | 3.05% | 247,300 +79,200 | +47% | +$10.7M |
|
5
Merck
MRK
$210B
| $31.4M | 2.86% | 377,000 -95,000 | -20% | -$7.9M |
|
6
Gilead Sciences
GILD
$140B
| $31.2M | 2.85% | 480,000 +130,000 | +37% | +$8.45M |
|
|
7
Viatris
VTRS
$12.3B
| $28.4M | 2.59% | 1,002,307 -674,934 | -40% | -$19.1M |
|
8
AstraZeneca
AZN
$248B
| $28.3M | 2.58% | 700,000 +185,000 | +36% | +$7.48M |
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $23.6M | 2.15% | 250,000 -215,000 | -46% | -$20.3M |
|
|
10
Novo Nordisk
NVO
$251B
| $20.9M | 1.91% | +400,000 | New | +$20.9M |
|
11
GSK
GSK
$79.9B
| $18M | 1.64% | 430,000 +120,000 | +39% | +$5.01M |
|
12
Verint Systems
VRNT
$1.23B
| $15.8M | 1.44% | 263,926 +114,826 | +77% | +$6.87M |
|
|
BLUE
13
DELISTED
bluebird bio
BLUE
| $13.2M | 1.2% | 83,796 -55,000 | -40% | -$8.65M |
|
|
14
UroGen Pharma
URGN
$900M
| $11.4M | 1.04% | +308,377 | New | +$11.4M |
|
|
ICPT
15
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $11.2M | 1.02% | +100,000 | New | +$11.2M |
|
16
Travere Therapeutics
TVTX
$1.56B
| $9.86M | 0.9% | 435,678 +110,000 | +34% | +$2.49M |
|
17
Aldeyra Therapeutics
ALDX
$351M
| $9.65M | 0.88% | 1,069,089 -163,000 | -13% | -$1.47M |
|
18
Novartis
NVS
$245B
| $9.61M | 0.88% | +100,000 | New | +$9.61M |
|
19
Sarepta Therapeutics
SRPT
$1.78B
| $8.75M | 0.8% | 73,405 -43,112 | -37% | -$5.14M |
|
20
PTC Therapeutics
PTCT
$3.92B
| $8.3M | 0.76% | 220,500 -125,000 | -36% | -$4.71M |
|
|
CLLS
21
Cellectis
CLLS
$258M
| $8.22M | 0.75% | 447,970 | – | – |
|
22
Ascendis Pharma
ASND
$11.8B
| $8.04M | 0.73% | 68,273 +10,000 | +17% | +$1.18M |
|
23
Spyre Therapeutics
SYRE
$996M
| $7.85M | 0.72% | 975,000 +375,000 | +63% | +$3.02M |
|
24
Allot
ALLT
$362M
| $7.67M | 0.7% | 965,931 +370,167 | +62% | +$2.94M |
|
25
Palo Alto Networks
PANW
$127B
| $7.47M | 0.68% | 30,754 +5,869 | +24% | +$1.43M |
|